María Victoria
Mateos Manteca
Profesora Titular de Universidad
Verónica
González de la Calle
Investigadora desde null
Publicaciones en las que colabora con Verónica González de la Calle (32)
2023
-
Definition and Clinical Significance of the Monoclonal Gammopathy of Undetermined Significance-Like Phenotype in Patients With Monoclonal Gammopathies
Journal of clinical oncology : official journal of the American Society of Clinical Oncology, Vol. 41, Núm. 16, pp. 3019-3031
-
Fractionated initial infusion and booster dose of ARI0002h, a humanised, BCMA-directed CAR T-cell therapy, for patients with relapsed or refractory multiple myeloma (CARTBCMA-HCB-01): a single-arm, multicentre, academic pilot study
The Lancet Oncology, Vol. 24, Núm. 8, pp. 913-924
-
Lenalidomide maintenance based on a genetic profile
Blood
-
Multiple myeloma with t(11;14): impact of novel agents on outcome
Blood Cancer Journal, Vol. 13, Núm. 1
-
Novel Agents as Main Drivers for Continued Improvement in Survival in Multiple Myeloma
Cancers, Vol. 15, Núm. 5
-
Randomized phase II study of weekly carfilzomib 70 mg/m2 and dexamethasone with or without cyclophosphamide in relapsed and/or refractory multiple myeloma patients
Haematologica, Vol. 108, Núm. 10, pp. 2753-2763
2022
-
Anti-BCMA CAR T-cell Therapy: Changing the Natural History of Multiple Myeloma
HemaSphere
-
MM-198 Anti-BCMA Therapy in Multiple Myeloma: A Single-Center Experience
Clinical Lymphoma, Myeloma and Leukemia, Vol. 22, pp. S413
-
MM-202 Impact of t(11;14) in Multiple Myeloma on Response to Treatment and Survival
Clinical Lymphoma, Myeloma and Leukemia, Vol. 22, pp. S413-S414
-
Mass spectrometry vs immunofixation for treatment monitoring in multiple myeloma
Blood Advances, Vol. 6, Núm. 11, pp. 3234-3239
-
Monoclonal gammopathy of renal significance (MGRS): Real-world data on outcomes and prognostic factors
American Journal of Hematology, Vol. 97, Núm. 7, pp. 877-884
-
Recovery of polyclonal immunoglobulins during treatment in patients ineligible for autologous stem-cell transplantation is a prognostic marker of longer progression-free survival and overall survival
British Journal of Haematology, Vol. 198, Núm. 2, pp. 278-287
2021
-
Dexamethasone as a partner of isatuximab
Blood
-
High-risk multiple myeloma: how to treat at diagnosis and relapse?
Hematology (United States), Vol. 2021, Núm. 1, pp. 30-36
-
Lenalidomide and dexamethasone with or without clarithromycin in patients with multiple myeloma ineligible for autologous transplant: a randomized trial
Blood Cancer Journal, Vol. 11, Núm. 5
2020
-
A multicenter retrospective study of 223 patients with t(14;16) in multiple myeloma
American Journal of Hematology, Vol. 95, Núm. 5, pp. 503-509
-
Comparison of next-generation sequencing (NGS) and next-generation flow (NGF) for minimal residual disease (MRD) assessment in multiple myeloma
Blood Cancer Journal, Vol. 10, Núm. 10
-
Different MAF translocations confer similar prognosis in newly diagnosed multiple myeloma patients
Leukemia and Lymphoma, Vol. 61, Núm. 8, pp. 1885-1893
-
EHA evaluation of the ESMO-Magnitude of Clinical Benefit Scale version 1.1 (ESMO-MCBS v1.1) for haematological malignancies
ESMO Open, Vol. 5, Núm. 1
-
International Myeloma Working Group risk stratification model for smoldering multiple myeloma (SMM)
Blood Cancer Journal, Vol. 10, Núm. 10